Access

News and Views

Nature 451, 1066-1067 (28 February 2008) | doi:10.1038/4511066a; Published online 27 February 2008

Open Innovation Challenges

naturejobs

More science jobs
Post a job for free

Cancer: Crossing over to drug resistance

David M. Livingston1 & Daniel P. Silver1

Top

Certain cancers stem from mutations that prevent a cell from repairing its damaged DNA efficiently. But antitumour chemotherapy that exploits that repair defect can in turn be nullified by counter-mutation.

Two papers1, 2 in this issue provide insight into a subset of breast and ovarian cancers, the action of drugs used to treat them, and a novel mechanism of chemotherapeutic drug resistance. The papers are by Edwards et al.1 and Sakai et al.2, and appear on pages 1111 and 1116.

  1. David M. Livingston and Daniel P. Silver are at the Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA.
    Email: david_livingston@dfci.harvard.edu
    Email: daniel_silver@dfci.harvard.edu